TiGenix prices US IPO at $15.50, a 14% discount to Brussels-traded shares

TiGenix, which is developing injectable stem cell therapies for the treatment of perianal fistulas, raised $36 million by offering 2.3 million shares at $15.50, a 14% discount to its Brussels-traded shares. TiGenix plans to list on the Nasdaq under the symbol TIG. It is also listed on the Euronext Brussels under symbol TIG. BofA Merrill Lynch and Cowen & Company acted as lead managers on the deal.